Acadia Pharmaceuticals (ACAD) Change in Acquisitions & Divestments (2010 - 2026)

Acadia Pharmaceuticals' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $86.5 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 33.87% year-over-year to $86.5 million in Q1 2026; TTM through Mar 2026 was $449.2 million, a 14.23% increase from a year earlier, with the FY2025 full-year figure at $493.5 million, up 50.21% from the prior year.
• Change in Acquisitions & Divestments retreated to $86.5 million in Q1 2026 per ACAD's latest filing, from $105.8 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $259.4 million in Q1 2023 and bottomed at $7.5 million in Q2 2023.
• The 5-year median for Change in Acquisitions & Divestments is $103.8 million (2023), against an average of $104.4 million.
• Across the five-year window, Change in Acquisitions & Divestments slumped 89.22% in 2023 and jumped 986.67% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $75.8 million in 2022, then soared by 36.89% to $103.8 million in 2023, then gained by 7.8% to $111.8 million in 2024, then slipped by 5.45% to $105.8 million in 2025, then dropped by 18.2% to $86.5 million in 2026.
• Per Business Quant, the three latest ACAD Change in Acquisitions & Divestments figures stand at $86.5 million (Q1 2026), $105.8 million (Q4 2025), and $125.6 million (Q3 2025).